AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment

Phase 2 Not yet recruiting 60 enrolled Akeso

NaSingle-groupOpen-labelTreatment

Summary

AK112 in non-squamous non-small cell lung cancer patients with actionable genomic alterations (AGA) who have failed to previous tyrosine kinase inhibitor (TKI) treatment

Timeline

Start: 2025-09-05
Primary completion: 2028-09
Completion: 2029-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ivonescimab	Monoclonal antibody	—	—

AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment

Summary

Timeline

Drugs

Indications